By Michael Erman and Christy Santhosh Jan 20 (Reuters) - Novavax said on Tuesday it signed a licensing agreement allowing ...

Maryland-based Novavax signed a licensing agreement allowing Pfizer access to its technology that boosts immune responses to ...

Pfizer is paying $30 million to use Novavax’s adjuvant technology to improve the efficacy of two of the Big Pharma’s vaccine ...

Under the terms of the agreement, Pfizer is expected to pay an upfront total of $30 million in early 2026 to Novavax, while ...

Novavax’s Pfizer Matrix-M licensing deal brings $30M upfront, milestones & royalties. Read the full analysis here.

Novavax entered the 2026 J.P. Morgan Healthcare Conference positioning itself as a partner-driven company focused on ...

Novavax (NVAX) shares added ~5% in the premarket on Tuesday after the COVID-19 vaccine maker reached a licensing deal with ...

Shares rose 6.6% Monday on new partnership strategy outlined at J.P. Morgan conference. Sanofi deal and cost cuts drive ...

The vaccines subsector received a big fillip from Covid, but its potential extends far beyond combating pandemics. Dr Mike ...

Shares of vaccine biotechnology company Novavax (NASDAQ:NVAX) jumped 19.7% in the afternoon session after the company ...

Novavax faces significant financial challenges, with high leverage and declining revenue growth. While strategic partnerships and asset restructuring provide some optimism, the overall outlook remains ...

The unprecedented changes have led to diminished vaccine usage, and created a drag that will likely dent revenues.